Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NervGen Pharma Corp. (V:NGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 595 Burrard Street
Tel: N/A
IR: See website
Key People
William Joseph Radvak
Executive Chairman of the Board, Co-Founder
Paul A. Brennan
President, Chief Executive Officer, Director
Amy Franke
Vice President - Clinical Operations
Business Overview
NervGen Pharma Corp. is a Canada-based biotechnology company. The Company is focused on developing solutions for the treatment of nerve damage and neurodegenerative diseases. The Company is also developing drugs for the treatment of spinal cord injury (SCI), multiple sclerosis (MS) and Alzheimer's disease. Its platform technology targets protein tyrosine phosphatase sigma (PTP sigma), a neural receptor that impedes nerve repair. The PTP sigma receptor promote regeneration of damaged nerves, increase plasticity and stimulate remyelination in animal models. The Company's lead product is NVG-291 referred to intracellular signaling peptide (ISP), treatment for SCI and MS.
Financial Overview
For the six months ended 30 June 2021, NervGenPharma Corp revenues was not reported. Net loss increased11% to C$5M. Higher net loss reflects Clinical increasefrom C$230K to C$482K (expense), Pre-clinical increase of80% to C$499K (expense), Other research and developmentincrease from C$24K to C$164K (expense). Basic Earnings perShare excluding Extraordinary Items remained flat at-C$0.14.
Reporting Currency: Canadian Dollars
Enterprise value: $90.59M as of Jun 30, 2021
Annual revenue (TTM): $0.00M as of Jun 30, 2021
EBITDA (TTM): -$11.42M as of Jun 30, 2021
Net annual income (TTM): -$11.69M as of Jun 30, 2021
Free cash flow (TTM): N/A
Net Debt Last Fiscal Year: N/A
Shares outstanding: 41,106,874 as of Oct 6, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization